Ark Bio of Shanghai Starts Phase II Trial of Novel RSV Treatment

Ark Biosciences, a Shanghai biopharma located in Zhangjiang Hi-Tec Park, has begun dosing patients in a global Phase II trial of AK0529, a novel treatment for respiratory syncytial virus (RSV). RSV is a common infection among infants, and although usually not serious, it is the leading cause of hospitalization in infants under the age of one. Ark in-licensed global rights to ARK0529 from Roche two years ago. In its Phase I trial, conducted in Australia, ARK0529 was well tolerated with predictable pharmacokinetics. More details.... Stock Symbol: (SX: ROG) Share this with colleagues: // //